Charles Schwab Investment Management Inc Novo Cure LTD Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 531,055 shares of NVCR stock, worth $9.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

531,055

Previous 551,775 3.76%

Holding current value

$9.1 Million

Previous $8.24 Million 0.75%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$12.42 - $17.29 $257,342 - $358,248	-20,720 Reduced 3.76%	531,055 $8.3 Million
Q4 2023 Feb 06, 2024	BUY	$11.13 - $15.78 $116,976 - $165,847	10,510 Added 1.94%	551,775 $8.24 Million
Q3 2023 Nov 08, 2023	SELL	$16.15 - $42.35 $32,106 - $84,191	-1,988 Reduced 0.37%	541,265 $8.74 Million
Q2 2023 Aug 09, 2023	BUY	$40.29 - $82.51 $241,095 - $493,739	5,984 Added 1.11%	543,253 $22.5 Million
Q1 2023 May 11, 2023	BUY	$56.44 - $118.81 $226,945 - $477,735	4,021 Added 0.75%	537,269 $32.3 Million

Q4 2022 Feb 13, 2023	BUY	$63.98 - $85.37 $1.34 Million - $1.78 Million	20,867 Added 4.07%	533,248 $39.1 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $476,405 - $627,616	7,007 Added 1.39%	512,381 $38.9 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $795,399 - $1.26 Million	14,053 Added 2.86%	505,374 $35.1 Million
Q1 2022 May 13, 2022	BUY	$60.15 - $84.52 $633,680 - $890,418	10,535 Added 2.19%	491,321 $40.7 Million
Q4 2021 Feb 11, 2022	BUY	$75.08 - $121.99 $803,130 - $1.3 Million	10,697 Added 2.28%	480,786 $36.1 Million
Q3 2021 Nov 16, 2021	SELL	$116.17 - $194.55 $19.5 Million - $32.7 Million	-168,041 Reduced 26.33%	470,089 $54.6 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $2.04 Million - $3.53 Million	15,631 Added 2.51%	638,130 $142 Million
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $5.83 Million - $8.93 Million	46,971 Added 8.16%	622,499 $82.3 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $1.05 Million - $1.64 Million	-9,406 Reduced 1.61%	575,528 $99.6 Million
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $31.7 Million - $60.9 Million	546,766 Added 1432.52%	584,934 $65.1 Million
Q2 2020 Aug 14, 2020	SELL	$57.2 - $74.41 $9.1 Million - $11.8 Million	-159,005 Reduced 80.64%	38,168 $2.26 Million
Q1 2020 May 15, 2020	BUY	$57.05 - $95.75 $16,088 - $27,001	282 Added 0.14%	197,173 $13.3 Million
Q4 2019 Feb 07, 2020	BUY	$68.3 - $93.8 $233,176 - $320,233	3,414 Added 1.76%	196,891 $16.6 Million
Q3 2019 Nov 08, 2019	BUY	$61.86 - $97.8 $1.06 Million - $1.67 Million	17,062 Added 9.67%	193,477 $14.5 Million
Q2 2019 Aug 09, 2019	BUY	$42.22 - $63.23 $1.2 Million - $1.8 Million	28,517 Added 19.28%	176,415 $11.2 Million
Q1 2019 May 14, 2019	BUY	$31.96 - $56.12 $167,246 - $293,675	5,233 Added 3.67%	147,898 $7.13 Million
Q4 2018 Feb 14, 2019	BUY	$28.72 - $52.63 $100,520 - $184,205	3,500 Added 2.52%	142,665 $4.78 Million
Q3 2018 Nov 13, 2018	BUY	$32.0 - $52.4 $168,480 - $275,886	5,265 Added 3.93%	139,165 $7.29 Million
Q2 2018 Aug 08, 2018	BUY	$19.85 - $32.0 $621,305 - $1 Million	31,300 Added 30.51%	133,900 $4.19 Million
Q1 2018 May 07, 2018	BUY	$19.3 - $23.65 $67,550 - $82,775	3,500 Added 3.53%	102,600 $2.24 Million
Q4 2017 Jan 17, 2018	BUY	$16.3 - $21.9 $34,230 - $45,990	2,100 Added 2.16%	99,100 $2 Million
Q3 2017 Nov 13, 2017	BUY	$18.05 - $21.75 $1.75 Million - $2.11 Million	97,000	97,000 $1.93 Million

Others Institutions Holding NVCR

# of Institutions

277

Shares Held

73.2M

Call Options Held

1.43M

Put Options Held

832K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.8B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Novo Cure LTD Transaction History